
“If we hadn’t received funding from Højteknologifonden (The Danish National Advanced Technology Foundation), there would never have been a company – at least not in relation to this. The funding has been crucial to the establishing of the project.”
Acarix co-founder Peter Samuelsen makes absolutely no bones about it when assessing the significance of the DKK 9m (USD 1.64m) that Højteknologifonden (HTF) posted in the company’s project between 2008 and 2011 – a project that has now resulted in advanced heart monitoring equipment, which in a very fast and simple manner evaluates the risk of coronary artery constriction in heart patients through a built-in microphone, a special patch, and an advanced technique for interpreting the collected signals.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app